Affiliation:
1. Department of Medical Biotechnologies, University of Siena, Siena, Italy
Funder
European Union’s Horizon 2020
Ministry of Science and Higher Education of the Russian Federation
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)
Reference9 articles.
1. Viral drug resistance through 48 weeks, in a phase 2b, randomized, controlled trial of the HIV-1 attachment inhibitor prodrug, fostemsavir;Lataillade;J Acquir Immune Defic Syndr,2018
2. Fostemsavir in adults with multidrug-resistant HIV-1 infection;Kozal;N Engl J Med,2020
3. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068;Nowicka-Sans;Antimicrob Agents Chemother,2012
4. Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay;Gartland;J Antimicrob Chemother,2021
5. Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016;Rossetti;HIV Med,2018